Drug Profile
PH 80
Alternative Names: ORG 39479; PH-80; PH-80-M; PH80-PMD NSLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Pherin Pharmaceuticals
- Developer Pherin Pharmaceuticals; VistaGen Therapeutics
- Class Antidepressants; Antimigraines; Steroids
- Mechanism of Action Neurotransmitter receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Hot flashes; Migraine; Premenstrual dysphoric disorder
Most Recent Events
- 09 Nov 2023 Vistagen plans a phase IIb trial for Hot flashes in USA (Intranasal, Spray) in the first half of 2025
- 09 Nov 2023 Vistagen plans IND-enabling studies for Hot flashes in the second half of 2024
- 18 Sep 2023 Vistagen Therapeutics plans to phase 2B trial in Hot flashes, before September 2023 (Vistagen Therapeutics pipeline, September 2023)